VASO VASO Corp

OTC Electromedical & Electrotherapeutic Apparatus DE CIK: 0000839087
AI RATING
HOLD
72% Confidence

Investment Thesis

VASO Corp maintains a fortress balance sheet with 35M cash and negligible debt, supporting positive 8.7M free cash flow despite operating losses. However, severe operational inefficiency—evidenced by -3.2% operating margin despite 61.4% gross margin—combined with minimal 2.7% revenue growth and share dilution suggests fundamental business restructuring is needed before the balance sheet strength can translate into shareholder value.

Strengths

  • + Strong 61.4% gross margin demonstrates competitive product positioning and pricing power in electromedical apparatus market
  • + Fortress balance sheet with 35M cash (39.6% of total assets), 1.59x current ratio, and negligible debt (15K long-term) providing substantial financial flexibility and downside protection
  • + Positive 8.7M free cash flow generation despite operating loss indicates underlying cash-generative capability despite operational challenges

Risks

  • ! Severe operational inefficiency with 64.7% operating expense ratio despite 61.4% gross margin, creating structural -3.2% operating margin and indicating fundamental cost control failures
  • ! Minimal 2.7% YoY revenue growth with only 1.8% net margin leaves minimal room for error and suggests limited competitive advantages or market expansion
  • ! Share dilution evident from flat EPS (0% YoY) despite 65% net income growth indicates value destruction through dilutive capital raises and excessive share count

Key Metrics to Watch

Financial Metrics

Revenue
89.1M
Net Income
1.6M
EPS (Diluted)
$0.01
Free Cash Flow
8.7M
Total Assets
88.3M
Cash
35.1M

Profitability Ratios

Gross Margin 61.4%
Operating Margin -3.2%
Net Margin 1.8%
ROE 5.3%
ROA 1.8%
FCF Margin 9.8%

Balance Sheet & Liquidity

Current Ratio
1.59x
Quick Ratio
1.57x
Debt/Equity
0.00x
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
15.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-18T12:09:33.637266 | Data as of: 2025-12-31 | Powered by Claude AI